Condition: Breast Cancer · Sponsor: Cambridge University Hospitals NHS Foundation Trust
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).
This description comes directly from the study's public registry record.
CCTC A Cambridge Cancer Trials Centre · +44 (0)1223 348071 · cuh.partner@nhs.net
Always discuss trial participation with your own doctor first.
| Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge | Cambridge, Cambridgeshire, United Kingdom | Recruiting |
| Queen's Hospital | Burton-on-Trent, Derby, United Kingdom | Recruiting |
| The Christie | Manchester, Lancs, United Kingdom | Recruiting |
| Pinderfields General Hospital | Wakefield, Yorkshire, United Kingdom | Recruiting |
| University Hospital Ayr | Ayr, United Kingdom | Recruiting |
| Basingstoke and North Hampshire Hospital | Basingstoke, United Kingdom | Recruiting |
| Bedford General Hospital | Bedford, United Kingdom | Recruiting |
| Royal Bournemouth Hospital | Bournemouth, United Kingdom | Recruiting |
| Bristol Haematology & Cancer Centre | Bristol, United Kingdom | Recruiting |
| West Suffolk Hospital | Bury St Edmunds, United Kingdom | Recruiting |
| Velindre Cancer Centre | Cardiff, United Kingdom | Recruiting |
| Colchester General Hospital | Colchester, United Kingdom | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03150576